KARLYN NAFEY: Open Payments
NPI 1568618460 · RONKONKOMA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$581 in 31 payments from 12 companies in 2025. Trend: 2023 $499 · 2024 $575 · 2025 $581
Food & beverage: $581
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $122 |
| ABBVIE INC. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Novo Nordisk Inc | 4 | $65 |
| Lilly USA, LLC | 3 | $57 |
| Amgen Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Currax Pharmaceuticals LLC | 2 | $35 |
| MEDICOMP INC | 1 | $33 |
| Exact Sciences Corporation | 1 | $20 |
Products named: XIFAXAN, REXULTI, OTEZLA, MOUNJARO, LINZESS, CONTRAVE, TELEPATCH CARDIAC MONITOR, Ozempic.
Industry payments across NY — which companies pay providers there.
